Progesterone vs Progestins and Breast Cancer Risk
The estrogen half of this question is on the estradiol page, and its conclusion is unexpected: estrogen alone did not raise breast cancer risk in the largest trial ever run, and may have lowered it. Which leaves an obvious follow-up. If the estrogen was not the problem in the combined-therapy arm, what was?
The answer, on the best available evidence, is the progestogen — and specifically which progestogen. That is the subject of this page, and it is why micronized progesterone rather than a synthetic progestin is what we prescribe.
Progesterone and progestins are not the same thing
Progesterone is the hormone the ovary makes. Micronized progesterone — sold as Prometrium and as generics — is that same molecule, processed into fine particles so it can be absorbed from a capsule.
A progestin is a synthetic molecule built to act on the progesterone receptor. Medroxyprogesterone acetate (Provera), norethindrone, levonorgestrel and others were designed for contraception and for hormone therapy at a time when natural progesterone could not be absorbed orally. They do the uterine-protection job. They also act, to varying degrees, on other receptors — androgen, glucocorticoid — and behave differently in breast tissue.
The Women's Health Initiative used medroxyprogesterone acetate. Every conclusion drawn from its combined-therapy arm is a conclusion about that progestin. It has been read for twenty years as a conclusion about "progesterone," which it never was.
What the E3N cohort found
The French E3N study followed more than 80,000 postmenopausal women, and because French practice used several different progestogens, it could compare them.
Estrogen combined with micronized progesterone or with dydrogesterone (a close relative) was not associated with a significant increase in breast cancer risk in the first five years of use. Estrogen combined with other synthetic progestins was — with a relative risk in the range the WHI had reported.
That pattern has been reproduced in other European cohorts, in the Finnish registry data, and in laboratory work showing that synthetic progestins stimulate proliferation in breast cells in ways progesterone does not. It is the reason guideline bodies now distinguish between progestogens rather than treating them as a class, and the reason the FDA's November 2025 label review cited the WHI's "outdated formulations" among its grounds for removing the boxed warning.
What stays uncertain
Honesty requires the next paragraph.
The Lancet's 2019 meta-analysis of 58 studies found some excess breast cancer risk with all forms of combined hormone therapy, including estrogen with micronized progesterone, when use extended beyond five years. The excess was smaller with progesterone than with progestins, and it was concentrated in longer use — but it was not zero. The E3N cohort itself, with longer follow-up, showed the progesterone advantage narrowing after five years.
So the fair summary is not "progesterone is safe and progestins are not." It is: the breast cancer signal in combined therapy is largely a progestin signal; micronized progesterone carries little or no excess in the first five years; and beyond five years, a small excess with any combined therapy cannot be excluded. That is a materially better position than the boxed warning described. It is not a clean bill.
What it means in practice
For a woman with a uterus on estradiol, progesterone is not optional — the main page explains why. The question is only which progestogen, and on breast risk the answer is micronized progesterone. It is what ACT 2 prescribes; we do not carry synthetic progestins.
For a woman weighing the whole decision, the numbers in absolute terms are on the estradiol breast cancer page. Read with this page, the picture is: a small risk, mostly attributable to a molecule we do not use, mostly appearing after five years, and to be revisited at that point rather than assumed at the start.
Breast screening continues on schedule throughout. That is not a caveat; it is the plan.
Frequently asked questions
Micronized progesterone combined with estrogen was not associated with a significant increase in breast cancer risk in the first five years in the E3N cohort. Synthetic progestins were. Beyond five years, a small excess with any combined therapy cannot be ruled out.
Progesterone is the body's own hormone. Progestins are synthetic molecules that act on the progesterone receptor and, to varying degrees, on others. They behave differently in breast tissue.
Medroxyprogesterone acetate. Its breast cancer finding is a finding about that molecule.
On the cohort evidence, yes — Prometrium is micronized progesterone; Provera is medroxyprogesterone acetate, the WHI progestin.
No. Micronized progesterone is the progestogen we use with estradiol.
The evidence is for oral micronized progesterone. Progesterone cream does not reliably protect the uterus and is not a substitute — see the progesterone cream page.
Where this fits in your plan
The Progesterone Capsule page covers the product; the estradiol breast cancer page covers the estrogen half and the absolute numbers. Current breast screening and a baseline panel come first.
We measure first. Then we act.
References
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment 2008;107:103–111.
- Fournier A et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment 2014;145:535–543.
- Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet 2019;394:1159–1168.
- Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women (WHI). JAMA 2002;288:321–333.
- Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric 2018;21:111–122.
- FDA. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10 2025.
- Back toProgesterone Capsule
- Estradiol and breast cancer riskThe boxed warning is gone; the question is not. What the WHI actually found for estrogen alone versus combined therapy, in absolute numbers, and what it means for you.Read
- The patch and clot riskOral estrogen roughly doubles clot risk. The patch, on the evidence, does not. Who that matters for — prior clot, obesity, smoking, thrombophilia — and who is still excluded.Read
- Progesterone cream: what it can and can't doA topical progesterone option, for use where endometrial protection is not the goal.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.